INTRODUCTION: We describe the use of serum cortisol and ACTH levels on postoperative d 1 and 2 as remission predictors after transsphenoidal surgery for Cushing's disease (CD). METHODS: Morning cortisol and ACTH levels were drawn daily after surgery; glucocorticoids were withheld until evidence of hypocortisolemia. Early remission was defined retrospectively as a subnormal morning cortisol level [< or =140 nmol/liter (< or =5 microg/dl)] on postoperative d 1 or 2 and sustained remission as subsequent eucortisolemia. RESULTS: Of 40 consecutive adults with CD (mean age 39 yr), 80% achieved early remission. Of 39 patients with a minimum follow-up of 14 months (mean 33 months), 31 (79.5%) achieved sustained remission at a mean follow-up of 32 months, including 30 of 31 (97%) with early remission and one of eight (12%) without early remission (P < 0.0001). Sustained remission was achieved in 26 of 28 (93%) patients having their first operation, compared with five of 11 (45%) with a prior unsuccessful operation (P < 0.001). For the 32 patients in early remission vs. the eight in nonremission, mean nadir cortisol levels were 57.6 +/- 33.0 (2.05 +/- 1.2 microg/dl) vs. 631.1 +/- 352.2 nmol/liter (22.9 +/- 12.8 microg/dl) (P < 0.0001), and nadir ACTH levels were 11.9 +/- 6.5 vs. 64.1 +/- 54.6 ng/liter (P < 0.001). Of 31 patients with sustained remission, 100% had subnormal morning cortisol levels, whereas 31% had subnormal ACTH levels (P < 0.0001). CONCLUSIONS: Serum morning cortisol levels on postoperative d 1 and 2 without glucocorticoid replacement provide a safe, simple, and reliable measure of early remission for CD and are predictive of sustained remission. This method allows for consideration of a repeat operation during the same hospitalization in patients with persistent hypercortisolemia.
INTRODUCTION: We describe the use of serum cortisol and ACTH levels on postoperative d 1 and 2 as remission predictors after transsphenoidal surgery for Cushing's disease (CD). METHODS: Morning cortisol and ACTH levels were drawn daily after surgery; glucocorticoids were withheld until evidence of hypocortisolemia. Early remission was defined retrospectively as a subnormal morning cortisol level [< or =140 nmol/liter (< or =5 microg/dl)] on postoperative d 1 or 2 and sustained remission as subsequent eucortisolemia. RESULTS: Of 40 consecutive adults with CD (mean age 39 yr), 80% achieved early remission. Of 39 patients with a minimum follow-up of 14 months (mean 33 months), 31 (79.5%) achieved sustained remission at a mean follow-up of 32 months, including 30 of 31 (97%) with early remission and one of eight (12%) without early remission (P < 0.0001). Sustained remission was achieved in 26 of 28 (93%) patients having their first operation, compared with five of 11 (45%) with a prior unsuccessful operation (P < 0.001). For the 32 patients in early remission vs. the eight in nonremission, mean nadir cortisol levels were 57.6 +/- 33.0 (2.05 +/- 1.2 microg/dl) vs. 631.1 +/- 352.2 nmol/liter (22.9 +/- 12.8 microg/dl) (P < 0.0001), and nadir ACTH levels were 11.9 +/- 6.5 vs. 64.1 +/- 54.6 ng/liter (P < 0.001). Of 31 patients with sustained remission, 100% had subnormal morning cortisol levels, whereas 31% had subnormal ACTH levels (P < 0.0001). CONCLUSIONS: Serum morning cortisol levels on postoperative d 1 and 2 without glucocorticoid replacement provide a safe, simple, and reliable measure of early remission for CD and are predictive of sustained remission. This method allows for consideration of a repeat operation during the same hospitalization in patients with persistent hypercortisolemia.
Authors: Alessandro Prete; Rosa Maria Paragliola; Filomena Bottiglieri; Carlo Antonio Rota; Alfredo Pontecorvi; Roberto Salvatori; Salvatore Maria Corsello Journal: Endocrine Date: 2016-07-09 Impact factor: 3.633
Authors: Lakshmi Srinivasan; Edward R Laws; Robert L Dodd; Monique M Monita; Christyn E Tannenbaum; Kjersti M Kirkeby; Olivia S Chu; Griffith R Harsh; Laurence Katznelson Journal: Pituitary Date: 2011-12 Impact factor: 4.107
Authors: Luis G Perez-Rivas; Marily Theodoropoulou; Francesco Ferraù; Clara Nusser; Kohei Kawaguchi; Constantine A Stratakis; Fabio Rueda Faucz; Luiz E Wildemberg; Guillaume Assié; Rudi Beschorner; Christina Dimopoulou; Michael Buchfelder; Vera Popovic; Christina M Berr; Miklós Tóth; Arif Ibrahim Ardisasmita; Jürgen Honegger; Jerôme Bertherat; Monica R Gadelha; Felix Beuschlein; Günter Stalla; Masayuki Komada; Márta Korbonits; Martin Reincke Journal: J Clin Endocrinol Metab Date: 2015-05-05 Impact factor: 5.958
Authors: Jung Soo Lim; Mi-Kyung Lee; Eunhee Choi; Namki Hong; Soo Il Jee; Sun Ho Kim; Eun Jig Lee Journal: Endocrine Date: 2018-11-24 Impact factor: 3.633
Authors: G Aranda; J Enseñat; M Mora; M Puig-Domingo; M J Martínez de Osaba; G Casals; E Verger; M T Ribalta; F A Hanzu; I Halperin Journal: Pituitary Date: 2015-02 Impact factor: 4.107